Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Related Keywords

United States ,United Kingdom ,China ,Taiwan ,Japan ,South Korea ,London ,City Of ,Republic Of Korea ,Wolfgang Dummer ,Emily Correia ,Raul Rodriguez ,Jodi Sievers ,Daiichi Sankyo ,Mutsuo Kanzawa ,Eli Lilly ,Rigel Pharmaceuticals Inc ,Nasdaq ,Exchange Commission ,Prnewswire Rigel Pharmaceuticals Inc ,Syneos Health ,Astrazeneca ,Imperial College London ,Kissei Pharmaceutical Co Ltd ,Rigel Pharmaceuticals ,Orphan Drug Designation ,Tissue Study ,Imperial College ,Quarterly Report ,Coronavirus Pandemic ,Business ,Health ,Pr Newswire ,Clinical Trials ,